This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMAG Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

We've had historically a decline price due to discounting, but I am happy to report that we took our first price increase every on May 1, so in Q3, we expect to see net price program starting to turn around and begin to grow, and so we'll have a nice multiplicative effect on our Feraheme sales, and so Feraheme is our flagship brand. We've got about 70 people across the U.S. who are selling Feraheme.

We've also have announced some recent approvals internationally in Europe, Canada and just last week in Switzerland, and so we will be seeing launches in double-digit royalties and milestones flowing to AMAG on the international basis. On top of that, we are building a company focused on the oncology/hematology in hospital space, which is where call on today in order to promote Feraheme, so we are looking to build out the portfolio with the purchaser in-licensing of commercial assets to leverage those call points.

The company on a whole will breakeven in 2012. For the first time, we will breakeven primarily or at least partially due to $33 million in milestones, so as we go forward and look to 2013, there's a $33 million GAAP if you like, but with sales continuing to grow, operating expenses continuing to decline, we like the idea of adding in an additional marketed asset or two in order to leverage the existence of this high-powered commercial team that we have out there and make the crossover into profitability, so that's really what we are focused on.

Feraheme is number one priority. It's continuing to grow. Feraheme in terms of grams and into profitability, so that's really what we are focused at Feraheme is number one priority. It's continuing to grow Feraheme in terms of grams, and that selling price and second is the successful business development initiative to identify commercial assets with strong IP and preferably in in-office injectable, so that we can leverage our current sales force and cross-over into profitability.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $118.00 1.10%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs